Nasdaq · Healthcare

Aquestive Therapeutics, Inc. (AQST)

As-reported financials and recent SEC filings for Aquestive Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$44.5M

Net income

$-83.8M

Net margin

—

Diluted EPS

$-0.78

ROE

248.9%

P/E (TTM)

—

Market cap

—

Debt / equity

-0.8×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$44.5M	$57.6M	$50.6M	$47.7M	$50.8M
Gross profit	$26.0M	$39.7M	$29.8M	$28.3M	—
Operating income	$-71.1M	$-30.8M	$-15.1M	$-42.1M	$-34.7M
Net income	$-83.8M	$-44.1M	$-7.9M	$-54.4M	$-70.5M
Diluted EPS	$-0.78	$-0.51	$-0.13	$-1.12	$-1.85

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

S-32026-06-26

42026-06-24

1442026-06-23

42026-06-16

1442026-06-15

42026-06-12

42026-06-12

42026-06-12

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on AQST

Search Aquestive Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.